Novo Nordisk, a Danish pharmaceutical firm, has announced that it will reduce the U.S. list price of some of its insulin products by up to 75%, effective January 1, 2024. This follows a similar move by Eli Lilly earlier this month, and is part of a larger effort to make insulin more affordable for people with diabetes. The price cuts are expected to provide relief to those who rely on insulin to manage their condition.